“Reports have emerged of myocarditis and pericarditis predominantly after the second dose of the coronavirus disease messenger ribonucleic acid vaccine. We describe 13 patients aged 12-17 years who presented with chest pain within 1 week after their second dose of the Pfizer vaccine and were found to have elevated serum troponin levels and evidence of myopericarditis…
Discussion: We report 13 adolescents with myopericarditis after the second dose of the Pfizer mRNA COVID-19 vaccine. This cluster of cases was identifiable as the age of eligibility for vaccination broadened with Emergency Use Authorization by the Food and Drug Administration. Our hospital is the only freestanding children's hospital in Washington and serves as a tertiary referral institution. To our knowledge, at least 3 other cases in this age group have been cared for at other hospitals in the state. Using these numbers and Washington Department of Health data on immunization, we estimate a possible incidence of 0.008% in adolescents aged 16-17 years and 0.01% in those aged 12-15 years following the second dose.
All patients had evidence of myocardial inflammation and edema on CMR, similar to findings in limited case series of adults with post–COVID-19 vaccine myocarditis. Although the symptoms resolved rapidly in all patients, their CMR findings indicate the potential for myocardial fibrosis and unknown long-term impact.”
All content on this site: Copyright © 2023 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.